SCHEMBL2965336

SCHEMBL2965336

CCC(=O)Nc1c(C(=O)O)cccc1-c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HNF4A P41235 1/20 0.50
FABP3 P05413 1/20 0.46
FABP4 P15090 1/20 0.46
FABP5 Q01469 1/20 0.46
IKBKB O14920 1/20 0.46
ADORA3 P0DMS8 3/20 0.46
ADORA2A P29274 3/20 0.46
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
ADORA2B P29275 2/20 0.46
ADORA1 P30542 2/20 0.46
ALDH1A1 P00352 5/20 0.45
MAPT P10636 2/20 0.45
POLB P06746 1/20 0.44
LTB4R2 Q9NPC1 1/20 0.44
GAA P10253 1/20 0.44
CHRNB2 P17787 1/20 0.44
CHRNB4 P30926 1/20 0.44
CHRNA3 P32297 1/20 0.44
CHRNA4 P43681 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL135374 0.85 PLK1 (0.45) HNF4ANPC1RAB9AALDH1A1MAPT
SCHEMBL18230845 0.85 POLB (0.51) NPC1RAB9AALDH1A1MAPTPOLB
SCHEMBL9958891 0.80 POLB (0.60) NPC1RAB9AALDH1A1MAPTPOLB
SCHEMBL1467307 0.80 HNF4A (0.54) HNF4AFABP3FABP4FABP5IKBKB
SCHEMBL3362915 0.79 HNF4A (0.58) HNF4AFABP3FABP4FABP5ALDH1A1
SCHEMBL8773868 0.78 ALB (0.47) ADORA3ADORA2ANPC1RAB9AADORA2B
SCHEMBL338541 0.77 MAPT (0.43) IKBKBADORA3ADORA2ANPC1RAB9A
SCHEMBL135375 0.77 ADORA3 (0.44) HNF4AIKBKBADORA3ADORA2ANPC1
SCHEMBL6206191 0.76 ALDH1A1 (0.69) NPC1RAB9AALDH1A1MAPTGAA
SCHEMBL31307595 0.75 HNF4A (0.46) HNF4AFABP3FABP4FABP5NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118290291-A Synthesis method of dihydro oat alkaloid D 微著生物科技(东营)有限责任公司 2024-07-05 CN disclosed
WO-2024110023-A1 AN ACTIVE COMPOSITION COMPRISING RETINOL SYMRISE AG (DE) 2024-05-30 WO disclosed
WO-2024078679-A1 A FRAGRANCE MIXTURE (VI) SYMRISE AG (DE) 2024-04-18 WO disclosed
WO-2024061476-A1 A METHOD FOR PREVENTING, MITIGATING AND/OR TREATING PTGS2-INDUCED SKIN DISORDERS AND RELATED DYSFUNCTIONS SYMRISE AG (DE) 2024-03-28 WO disclosed
WO-2024051922-A1 A FRAGRANCE MIXTURE (III) SYMRISE AG (DE) 2024-03-14 WO disclosed
EP-4330265-A1 MICROBIAL GLYCOLIPIDS Analyticon Discovery GmbH (DE) 2024-03-06 EP disclosed
EP-4326251-A1 COMPOSITIONS COMPRISING CANNABIDIOL AND, OPTIONALLY, BISABOLOL Symrise AG (DE) 2024-02-28 EP disclosed
WO-2024037712-A1 1-CYCLOOCTYLPROPAN-2-ONE AS A FRAGRANCE SYMRISE AG (DE) 2024-02-22 WO disclosed
EP-4322911-A1 A FRAGRANCE MIXTURE CONTAINING ISOCITRONELLOL Symrise AG (DE) 2024-02-21 EP disclosed
WO-2024027922-A1 A FRAGRANCE MIXTURE (II) SYMRISE AG (DE) 2024-02-08 WO disclosed
WO-2022111829-A1 ESSENTIAL OILS OF CITRUS FRUITS FOR USE AS MEDICAMENT FOR INDUCED, INCREASED AND/OR ACCELERATED AUTOPHAGY IN HUMAN KERATINOCYTES SYMRISE AG (DE) 2022-06-02 WO disclosed
EP-3982910-A1 A COOLING PREPARATION Symrise AG (DE) 2022-04-20 EP disclosed
EP-3938055-A1 AN ANTIMICROBIAL MIXTURE Symrise AG (DE) 2022-01-19 EP disclosed
WO-2021228840-A1 A FRAGRANCE COMPOSITION SYMRISE AG (DE) 2021-11-18 WO disclosed
WO-2020249216-A1 A COOLING PREPARATION SYMRISE AG (DE) 2020-12-17 WO disclosed
WO-2020182318-A1 AN ANTIMICROBIAL MIXTURE SYMRISE AG (DE) 2020-09-17 WO disclosed
US-9445988-B2 Extracts of Tetraselmis sp SYMRISE AG (DE) 2016-09-20 US disclosed
US-9125936-B2 Ginger extract for the protection of stem cells SYMRISE AG (DE) 2015-09-08 US disclosed
US-20140242020-A1 Ginger Extract for the Protection of Stem Cells SYMRISE AG (DE) 2014-08-28 US disclosed
US-20100143267-A1 EXTRACTS OF TETRASELMIS SP. SYMRISE GMBH & CO. KG (DE) 2010-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140242020-A1 Ginger Extract for the Protection of Stem Cells HSD11B1, HSD3B1, EBP HNF4A 19/4885FABP3 861/4885FABP4 736/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.